{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,2]],"date-time":"2026-05-02T16:18:14Z","timestamp":1777738694241,"version":"3.51.4"},"reference-count":28,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2021,5,1]],"date-time":"2021-05-01T00:00:00Z","timestamp":1619827200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,5,1]],"date-time":"2021-05-01T00:00:00Z","timestamp":1619827200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,5,1]],"date-time":"2021-05-01T00:00:00Z","timestamp":1619827200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2021,5,1]],"date-time":"2021-05-01T00:00:00Z","timestamp":1619827200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2021,5,1]],"date-time":"2021-05-01T00:00:00Z","timestamp":1619827200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2021,5,1]],"date-time":"2021-05-01T00:00:00Z","timestamp":1619827200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2021,5,1]],"date-time":"2021-05-01T00:00:00Z","timestamp":1619827200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100000026","name":"National Institute on Drug Abuse","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000026","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","journalofsubstanceabusetreatment.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Substance Abuse Treatment"],"published-print":{"date-parts":[[2021,5]]},"DOI":"10.1016\/j.jsat.2021.108292","type":"journal-article","created":{"date-parts":[[2021,1,18]],"date-time":"2021-01-18T01:04:11Z","timestamp":1610931851000},"page":"108292","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":11,"special_numbering":"C","title":["Association between methadone or buprenorphine use during medically supervised opioid withdrawal and extended-release injectable naltrexone induction failure"],"prefix":"10.1016","volume":"124","author":[{"given":"Matisyahu","family":"Shulman","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tse-Hwei","family":"Choo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jennifer","family":"Scodes","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Martina","family":"Pavlicova","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jonathan","family":"Wai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Patrick","family":"Haenlein","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Babak","family":"Tofighi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Aimee N.C.","family":"Campbell","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joshua D.","family":"Lee","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"John","family":"Rotrosen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Edward V.","family":"Nunes","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.jsat.2021.108292_bb0005","series-title":"Vivitrol full prescribing information","author":"Alkermes","year":"2010"},{"issue":"Suppl. 1","key":"10.1016\/j.jsat.2021.108292_bb0010","first-page":"S42","article-title":"Bringing buprenorphine-naloxone detoxification to community treatment providers: The NIDA Clinical Trials Network field experience","volume":"13","author":"Amass","year":"2004","journal-title":"The American Journal on Addictions"},{"issue":"2","key":"10.1016\/j.jsat.2021.108292_bb0015","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1007\/BF02190738","article-title":"Methadone maintenance treatment: An update","volume":"245","author":"Bertschy","year":"1995","journal-title":"European Archives of Psychiatry and Clinical Neuroscience"},{"issue":"3","key":"10.1016\/j.jsat.2021.108292_bb0020","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1111\/ajad.12711","article-title":"Antagonists in the medical management of opioid use disorders: Historical and existing treatment strategies","volume":"27","author":"Bisaga","year":"2018","journal-title":"The American Journal on Addictions"},{"key":"10.1016\/j.jsat.2021.108292_bb0025","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1016\/j.drugalcdep.2018.02.023","article-title":"Outpatient transition to extended-release injectable naltrexone for patients with opioid use disorder: A phase 3 randomized trial","volume":"187","author":"Bisaga","year":"2018","journal-title":"Drug and Alcohol Dependence"},{"issue":"4","key":"10.1016\/j.jsat.2021.108292_bb0030","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1007\/s002130100909","article-title":"Depot naltrexone: Long-lasting antagonism of the effects of heroin in humans","volume":"159","author":"Comer","year":"2002","journal-title":"Psychopharmacology"},{"issue":"2","key":"10.1016\/j.jsat.2021.108292_bb0035","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1093\/jurban\/jti049","article-title":"Illicit opioid use in Canada: Comparing social, health, and drug use characteristics of untreated users in five cities (OPICAN study)","volume":"82","author":"Fischer","year":"2005","journal-title":"Journal of Urban Health: Bulletin of the New York Academy of Medicine"},{"issue":"4","key":"10.1016\/j.jsat.2021.108292_bb0040","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1001\/jama.1980.03300300021018","article-title":"Opiate withdrawal using clonidine. A safe, effective, and rapid nonopiate treatment","volume":"243","author":"Gold","year":"1980","journal-title":"JAMA"},{"issue":"4","key":"10.1016\/j.jsat.2021.108292_bb0045","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1016\/0376-8716(80)90323-3","article-title":"Efficacy of clonidine in opiate withdrawal: A study of thirty patients","volume":"6","author":"Gold","year":"1980","journal-title":"Drug and Alcohol Dependence"},{"key":"10.1016\/j.jsat.2021.108292_bb0050","article-title":"Alpha2-adrenergic agonists for the management of opioid withdrawal","volume":"2","author":"Gowing","year":"2009","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"2","key":"10.1016\/j.jsat.2021.108292_bb0055","first-page":"1","article-title":"The use of clonidine in detoxification from opiates","volume":"32","author":"Kleber","year":"1980","journal-title":"Bulletin on Narcotics"},{"issue":"2","key":"10.1016\/j.jsat.2021.108292_bb0060","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1080\/10550881003684798","article-title":"Pharmacotherapy in the treatment of addiction: Methadone","volume":"29","author":"Kreek","year":"2010","journal-title":"Journal of Addictive Diseases"},{"issue":"9776","key":"10.1016\/j.jsat.2021.108292_bb0065","doi-asserted-by":"crossref","first-page":"1506","DOI":"10.1016\/S0140-6736(11)60358-9","article-title":"Injectable extended-release naltrexone for opioid dependence: A double-blind, placebo-controlled, multicentre randomised trial","volume":"377","author":"Krupitsky","year":"2011","journal-title":"Lancet"},{"key":"10.1016\/j.jsat.2021.108292_bb0070","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1016\/j.cct.2016.08.004","article-title":"NIDA clinical trials network CTN-0051, extended-release naltrexone vs. buprenorphine for opioid treatment (X:BOT): Study design and rationale","volume":"50","author":"Lee","year":"2016","journal-title":"Contemporary Clinical Trials"},{"issue":"10118","key":"10.1016\/j.jsat.2021.108292_bb0075","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1016\/S0140-6736(17)32812-X","article-title":"Comparative effectiveness of extended-release naltrexone versus buprenorphine-naloxone for opioid relapse prevention (X:BOT): A multicentre, open-label, randomised controlled trial","volume":"391","author":"Lee","year":"2018","journal-title":"Lancet"},{"issue":"8","key":"10.1016\/j.jsat.2021.108292_bb0080","doi-asserted-by":"crossref","first-page":"1090","DOI":"10.1111\/j.1360-0443.2005.01154.x","article-title":"A multi-center randomized trial of buprenorphine-naloxone versus clonidine for opioid detoxification: Findings from the National Institute on Drug Abuse Clinical Trials Network","volume":"100","author":"Ling","year":"2005","journal-title":"Addiction"},{"issue":"2","key":"10.1016\/j.jsat.2021.108292_bb0085","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1111\/j.1369-1600.2008.00119.x","article-title":"Very low dose naltrexone addition in opioid detoxification: A randomized, controlled trial","volume":"14","author":"Mannelli","year":"2009","journal-title":"Addiction Biology"},{"key":"10.1016\/j.jsat.2021.108292_bb0090","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/j.drugalcdep.2014.02.002","article-title":"Extended release naltrexone injection is performed in the majority of opioid dependent patients receiving outpatient induction: A very low dose naltrexone and buprenorphine open label trial","volume":"138","author":"Mannelli","year":"2014","journal-title":"Drug and Alcohol Dependence"},{"key":"10.1016\/j.jsat.2021.108292_bb0095","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1016\/j.jsat.2018.01.003","article-title":"A qualitative assessment of attitudes about and preferences for extended-release naltrexone, a new pharmacotherapy to treat opioid use disorders in Ukraine","volume":"86","author":"Marcus","year":"2018","journal-title":"Journal of Substance Abuse Treatment"},{"key":"10.1016\/j.jsat.2021.108292_bb0100","article-title":"Methadone maintenance therapy versus no opioid replacement therapy for opioid dependence","volume":"3","author":"Mattick","year":"2009","journal-title":"Cochrane Database of Systematic Reviews"},{"key":"10.1016\/j.jsat.2021.108292_bb0105","doi-asserted-by":"crossref","DOI":"10.1002\/14651858.CD002207.pub3","article-title":"Buprenorphine maintenance versus placebo or methadone maintenance for opioid dependence","volume":"2","author":"Mattick","year":"2008","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"3","key":"10.1016\/j.jsat.2021.108292_bb0110","article-title":"Survey of treatment preferences for opioid use disorder","volume":"5","author":"Nahata","year":"2018","journal-title":"Jacobs Journal of Addiction and Therapy"},{"key":"10.1016\/j.jsat.2021.108292_bb0115","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1016\/j.cct.2016.09.006","article-title":"Ethical and clinical safety considerations in the design of an effectiveness trial: A comparison of buprenorphine versus naltrexone treatment for opioid dependence","volume":"51","author":"Nunes","year":"2016","journal-title":"Contemporary Clinical Trials"},{"issue":"50\u201351","key":"10.1016\/j.jsat.2021.108292_bb0120","doi-asserted-by":"crossref","first-page":"1445","DOI":"10.15585\/mmwr.mm655051e1","article-title":"Increases in drug and opioid-involved overdose deaths - United States, 2010\u20132015","volume":"65","author":"Rudd","year":"2016","journal-title":"MMWR. Morbidity and Mortality Weekly Report"},{"issue":"3","key":"10.1016\/j.jsat.2021.108292_bb0125","doi-asserted-by":"crossref","first-page":"187","DOI":"10.3109\/00952990.2011.653426","article-title":"Opioid detoxification and naltrexone induction strategies: Recommendations for clinical practice","volume":"38","author":"Sigmon","year":"2012","journal-title":"The American Journal of Drug and Alcohol Abuse"},{"issue":"5","key":"10.1016\/j.jsat.2021.108292_bb0130","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1176\/appi.ajp.2016.16050548","article-title":"Long-acting injectable naltrexone induction: A randomized trial of outpatient opioid detoxification with naltrexone versus buprenorphine","volume":"174","author":"Sullivan","year":"2017","journal-title":"The American Journal of Psychiatry"},{"issue":"22","key":"10.1016\/j.jsat.2021.108292_bb0135","doi-asserted-by":"crossref","first-page":"2063","DOI":"10.1056\/NEJMp1402780","article-title":"Medication-assisted therapies\u2014tackling the opioid-overdose epidemic","volume":"370","author":"Volkow","year":"2014","journal-title":"The New England Journal of Medicine"},{"issue":"1\u20133","key":"10.1016\/j.jsat.2021.108292_bb0140","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1016\/j.drugalcdep.2008.06.016","article-title":"Predictors of outcome for short-term medically supervised opioid withdrawal during a randomized, multicenter trial of buprenorphine-naloxone and clonidine in the NIDA clinical trials network drug and alcohol dependence","volume":"99","author":"Ziedonis","year":"2009","journal-title":"Drug and Alcohol Dependence"}],"container-title":["Journal of Substance Abuse Treatment"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0740547221000180?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0740547221000180?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T19:53:37Z","timestamp":1760039617000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0740547221000180"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,5]]},"references-count":28,"alternative-id":["S0740547221000180"],"URL":"https:\/\/doi.org\/10.1016\/j.jsat.2021.108292","relation":{},"ISSN":["0740-5472"],"issn-type":[{"value":"0740-5472","type":"print"}],"subject":[],"published":{"date-parts":[[2021,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Association between methadone or buprenorphine use during medically supervised opioid withdrawal and extended-release injectable naltrexone induction failure","name":"articletitle","label":"Article Title"},{"value":"Journal of Substance Abuse Treatment","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jsat.2021.108292","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"108292"}}